Alpine Immune Sciences Inc (ALPN)
64.58
-0.12
(-0.19%)
USD |
NASDAQ |
Apr 30, 16:00
64.58
0.00 (0.00%)
After-Hours: 20:00
Alpine Immune Sciences Cash from Investing (Quarterly): -112.70M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -112.70M |
| September 30, 2023 | -0.535M |
| June 30, 2023 | 29.33M |
| March 31, 2023 | 28.35M |
| December 31, 2022 | -107.90M |
| September 30, 2022 | 25.79M |
| June 30, 2022 | 6.564M |
| March 31, 2022 | -37.80M |
| December 31, 2021 | -4.285M |
| September 30, 2021 | -62.52M |
| June 30, 2021 | 20.87M |
| March 31, 2021 | -6.546M |
| December 31, 2020 | -96.85M |
| September 30, 2020 | 1.843M |
| June 30, 2020 | 9.057M |
| March 31, 2020 | 13.13M |
| December 31, 2019 | 4.388M |
| September 30, 2019 | 10.86M |
| June 30, 2019 | -17.59M |
| March 31, 2019 | 19.10M |
| Date | Value |
|---|---|
| December 31, 2018 | 9.136M |
| September 30, 2018 | 15.77M |
| June 30, 2018 | 3.338M |
| March 31, 2018 | 3.87M |
| December 31, 2017 | 1.855M |
| September 30, 2017 | -46.63M |
| June 30, 2017 | 17.81M |
| March 31, 2017 | -2.838M |
| December 31, 2016 | 13.15M |
| September 30, 2016 | 8.265M |
| June 30, 2016 | 5.841M |
| March 31, 2016 | -1.95M |
| December 31, 2015 | -27.22M |
| September 30, 2015 | -35.14M |
| June 30, 2015 | -0.035M |
| March 31, 2015 | -0.052M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | -0.0029M |
| March 31, 2014 | -0.0011M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-112.70M
Minimum
Dec 2023
29.33M
Maximum
Jun 2023
-15.61M
Average
1.843M
Median
Sep 2020
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -886.50M |
| Eliem Therapeutics Inc | 36.75M |
| Regeneron Pharmaceuticals Inc | -66.20M |
| Vera Therapeutics Inc | 18.56M |
| Eyenovia Inc | -0.1452M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.97M |
| Cash from Financing (Quarterly) | 156.61M |
| Free Cash Flow | -79.50M |
| Free Cash Flow Per Share (Quarterly) | -0.3461 |
| Free Cash Flow to Equity (Quarterly) | -19.08M |
| Free Cash Flow to Firm (Quarterly) | -19.08M |
| Free Cash Flow Yield | -2.46% |